Interestingly, focal 11q23 amplification without characteristic oncogenic MLL fusions (Liu et al., 2009) is thought to occur in approximately 1% of AML and Myelodysplastic syndrome (MDS) and is associated with adverse outcomes (Yip and So, 2013). The gene discussed is KMT2A; the disease is myelodysplastic syndrome.